TrialPath
Recruiting

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT07746687 · Janssen Research & Development, LLC
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Inadequately Controlled Moderate to Severe Asthma
About this study
The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).
Eligibility criteria
Inclusion criteria: * Medically stable on the basis of physical examination, medical history, and vital signs performed at screening or at baseline * Confirmed variable expiratory flow (1 or more of the following) per global initiative for asthma (GINA) 2025 at the baseline visit: a. Evidence of bronchodilator responsiveness at screening and baseline: Post-bronchodilator forced expiratory volume in 1 second (FEV1) increases by greater than or equal to (\>=) 200 milliliter (mL) and \>=12 percent (%) of pre- bronchodilator value, or increase in peak expiratory flow (PEF) \>=20%, if spirometry is not available; b. Demonstrated increase in lung function within the past 3 years after \>=4 weeks of daily inhaled corticosteroids (ICS)-containing treatment, shown by: increase from baseline FEV1 by \>=12% and \>=200 mL, or increase in PEF by \>=20%; c. Positive bronchial provocation test within the past 3 years, as defined by: \>=20% decrease from baseline in FEV1 with standard doses of methacholine, or \>=15% decrease from baseline in FEV1 with standardized hyperventilation, hypertonic saline or mannitol challenge, or decrease from baseline in FEV1 of \>10% and \>200 mL with standardized exercise challenge * Inhaled corticosteroid: Prescribed medium- or high-dose ICS for at least 1 year and a stable dose of medium- or high-dose ICS for at least 3 months prior to the screening visit per GINA 2025: • High-dose ICS is defined as a total daily dose \>=500 microgram (mcg) fluticasone propionate or equivalent, • Medium-dose ICS is defined as a total daily dose \>=250 to 500 mcg fluticasone propionate or equivalent * Additional controller medication: Must be on a stable dose of at least 1 additional maintenance asthma controller, in addition to ICS, per GINA 2025, for at least 3 months prior to screening (for example, long-acting beta-agonist \[LABA\], long-acting muscarinic antagonist \[LAMA\] \[can be combined with ICS in 1 inhaler or can be separate inhalers\], leukotriene receptor antagonist \[LTRA\]) * Asthma control questionnaire, 5-item (ACQ-5) score \>=1.5 at the screening visit and the baseline visit Exclusion criteria: * History of uncontrolled, significant renal, cardiac, vascular, pulmonary (other than asthma), gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances that makes the participant unsuitable for the trial per investigator judgment * Any clinically important pulmonary disease other than asthma or pulmonary or systemic diseases, other than asthma, that are associated with elevated peripheral eosinophil counts * Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents inhibiting interleukin (IL)-13, IL-4Rα, and IL-4 signaling * Participants with either of the following events within the 2 weeks prior to the screening visit: a. Treatment with systemic steroids (oral or parenteral) for worsening asthma, b. Hospitalization or an emergency medical care visit for worsening asthma * Current smokers or former smokers with a smoking history \>=20 pack-years. Former smokers must have stopped smoking within 6 months of the screening visit. This includes participants using vaping products and e-cigarettes
Study design
Enrollment target: 440 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-10-05
Estimated completion: 2030-07-01
Last updated: 2026-11-03
Interventions
Drug: JNJ-95597528Drug: Placebo
Primary outcomes
  • • Number of Asthma Exacerbations Through Week 48 (Up to Week 48)
Sponsor
Janssen Research & Development, LLC · industry
Contacts & investigators
ContactStudy Contact · contact · Participate-In-This-Study1@its.jnj.com · 844-434-4210
InvestigatorJanssen Research & Development, LLC Clinical Trial · study_director, Janssen Research & Development, LLC
All locations (19)
Allianz Research Institute, Inc.Recruiting
Westminster, California, United States
Boston SpecialistsRecruiting
Boston, Massachusetts, United States
Clinical Research InstituteRecruiting
Minneapolis, Minnesota, United States
Midwest Clinical Research LLCRecruiting
St Louis, Missouri, United States
Equity MedicalRecruiting
The Bronx, New York, United States
OK Clinical ResearchRecruiting
Edmond, Oklahoma, United States
Allergy Asthma and Clinical Research Center Martha Tarpay MDRecruiting
Oklahoma, Texas, United States
INAER - Investigacion en Alergias y Enfermedades RespiratoriasRecruiting
Buenos Aires, Argentina
Instituto de Medicina Respiratoria IMERRecruiting
Córdoba, Argentina
Fundacion ScherbovskyRecruiting
Mendoza, Argentina
Instituto De Especialidades De La Salud SRLRecruiting
Rosario, Argentina
IBAMEDICA Propiedad de IBA Santa Fe S.A.SRecruiting
Santa Fe, Argentina
China Japan Friendship HospitalRecruiting
Beijing, China
Changzhou No 2 Peoples HospitalRecruiting
Changzhou, China
Ningbo medical center lihuili hospitalRecruiting
Ningbo, China
Shanxi Bethune HospitalRecruiting
Taiyuan, China
Tel Aviv Sourasky Medical CenterRecruiting
Tel Aviv, Israel
Idaimae Minami4jo Internal MedicineRecruiting
Sapporo, Japan
Tokyo Shinagawa HospitalRecruiting
Shinagawa City, Japan
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma · TrialPath